A novel bispecific GIP receptor antagonist and GLP-1 receptor agonist induced weight loss of up to 14.5% in adults with obesity with no safety concerns, according to data from a phase 1 trial. In ...

Macitentan demonstrated superiority over other endothelin receptor antagonists (ERAs) in the treatment of pulmonary arterial hypertension (PAH), according to findings from the first real-world ...